Your session is about to expire
← Back to Search
Combination Therapy for Non-Hodgkin's Lymphoma
Study Summary
This trial is looking at the safety and effectiveness of a new combination treatment for relapsed or refractory B-cell non-Hodgkin's lymphoma. This combination includes the drugs glofitamab and obinutuzumab.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 229 Patients • NCT02264574Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have severe nerve damage in my hands or feet.I have had lung conditions like pulmonary fibrosis or pneumonia, or my CT scan shows active lung inflammation.I have had a stem cell transplant from a donor.I had a stem cell transplant using my own cells less than 100 days ago.I can take care of myself and am up and about more than half of the day.My liver, blood, and kidney functions are all within normal ranges.I have or had a brain or spinal cord disease.My condition did not improve after treatment with obinutuzumab alone.I haven't had cancer or lymphoma treatment or immune therapy in the last 4 weeks or 5 half-lives of the drug.I am currently taking medication that weakens my immune system.I have a recent biopsy or an older one not affected by major changes.My blood cancer is expected to have CD20 and has not improved after treatment.I have been diagnosed with progressive multifocal leukoencephalopathy.I have had severe immune-related side effects from treatment, except for hormone issues managed with medication.I haven't had cancer treatment or experimental therapy in the last 4 weeks.I have or had brain lymphoma.I haven't taken more than 25mg/day of steroids like prednisone in the last 4 weeks.I have an autoimmune condition, but it's not hypothyroidism or Type 1 diabetes.I have had cancer spread to the lining of my brain and spinal cord.I haven't had a live vaccine in the last 4 weeks and won't need one during the study.I have not had major surgery or a serious injury in the last 28 days.I have had a solid organ transplant.I have a specific type of leukemia or lymphoma.I have serious heart or lung disease.I have not had an active infection or a flare-up of a hidden infection in the last 4 weeks.
- Group 1: Atezolizumab
- Group 2: Polatuzumab Vedotin
- Group 3: Imaging Sub-study
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants is the maximum capacity for this research endeavor?
"Confirmed. Per the information published on clinicaltrials.gov, this investigation is presently recruiting participants and was first posted on May 8th 2018. For a successful trial completion, 280 individuals need to be recruited from 1 medical centre."
To what end is Obinutuzumab usually administered?
"Obinutuzumab is commonly employed to treat dlbcl, but can also be utilized in the care of sjia and certain malignant neoplasms such as small cell lung cancer."
Could you provide information about preceding research on Obinutuzumab?
"At this time, 513 Obinutuzumab experiments are in progress. Of these trials, 98 have reached phase 3 and 24630 different sites across the world are conducting them. The majority of locations for these tests are located in Harvey, Illinois."
Is there availability for participants in this examination?
"According to clinicaltrials.gov, this research is currently accepting participants. The original posting date was 8th of May 2018 and the latest update occurred on November 1st 2022."
Has this form of experimentation been done before?
"Currently, 513 active studies utilizing Obinutuzumab are running across 82 nations and 1947 cities. This medication was initially trialled in 2008 by Hoffmann-La Roche with 720 test subjects over the course of two stages - Phase 2 drug approval being one of them. Since then, 349 trials have concluded."
Share this study with friends
Copy Link
Messenger